Stock Track | Day One Biopharmaceuticals Soars 5.04% on Promising OJEMDA™ Trial Results for Pediatric Brain Cancer

Stock Track

Nov 10

Day One Biopharmaceuticals Inc. (DAWN) stock is soaring 5.04% in pre-market trading on Monday, following the announcement of new data from its OJEMDA™ (tovorafenib) trial in pediatric low-grade glioma (pLGG) to be presented at the upcoming Society for Neuro-Oncology (SNO) Annual Meeting.

The company revealed that updated results from the registrational Phase 2 FIREFLY-1 trial will be presented in an oral session at the SNO meeting, scheduled for November 19-23, 2025. The trial evaluates tovorafenib as a once-weekly oral monotherapy in patients aged 6 months to 25 years with relapsed or progressive pLGG with a known activating BRAF alteration. The presentation will showcase more than 36 months of follow-up data, demonstrating durable responses and clinical stability off treatment, as well as newly disclosed treatment-free interval data.

Investors are reacting positively to this news, as the extended follow-up data and treatment-free interval information could potentially strengthen OJEMDA's position in the pediatric brain cancer treatment landscape. The presentation by Dr. Cassie Klein from the Children's Hospital of Pennsylvania on November 23, 2025, is highly anticipated and could provide further insights into the drug's efficacy and long-term benefits for young patients with this challenging form of brain cancer.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1119742553"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1119742553\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1119742553?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-10 23:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1119742553","market":"us","top_or_hot":-1,"title":"Stock Track | Day One Biopharmaceuticals Soars 5.04% on Promising OJEMDA™ Trial Results for Pediatric Brain Cancer","media":"Stock Track","content":"<p>Day One Biopharmaceuticals Inc. (DAWN) stock is soaring 5.04% in pre-market trading on Monday, following the announcement of new data from its OJEMDA™ (tovorafenib) trial in pediatric low-grade glioma (pLGG) to be presented at the upcoming Society for Neuro-Oncology (SNO) Annual Meeting.</p>\n\n<p>The company revealed that updated results from the registrational Phase 2 FIREFLY-1 trial will be presented in an oral session at the SNO meeting, scheduled for November 19-23, 2025. The trial evaluates tovorafenib as a once-weekly oral monotherapy in patients aged 6 months to 25 years with relapsed or progressive pLGG with a known activating BRAF alteration. The presentation will showcase more than 36 months of follow-up data, demonstrating durable responses and clinical stability off treatment, as well as newly disclosed treatment-free interval data.</p>\n\n<p>Investors are reacting positively to this news, as the extended follow-up data and treatment-free interval information could potentially strengthen OJEMDA's position in the pediatric brain cancer treatment landscape. The presentation by Dr. Cassie Klein from the Children's Hospital of Pennsylvania on November 23, 2025, is highly anticipated and could provide further insights into the drug's efficacy and long-term benefits for young patients with this challenging form of brain cancer.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Day One Biopharmaceuticals Soars 5.04% on Promising OJEMDA™ Trial Results for Pediatric Brain Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Day One Biopharmaceuticals Soars 5.04% on Promising OJEMDA™ Trial Results for Pediatric Brain Cancer\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-10 23:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Day One Biopharmaceuticals Inc. (DAWN) stock is soaring 5.04% in pre-market trading on Monday, following the announcement of new data from its OJEMDA™ (tovorafenib) trial in pediatric low-grade glioma (pLGG) to be presented at the upcoming Society for Neuro-Oncology (SNO) Annual Meeting.</p>\n\n<p>The company revealed that updated results from the registrational Phase 2 FIREFLY-1 trial will be presented in an oral session at the SNO meeting, scheduled for November 19-23, 2025. The trial evaluates tovorafenib as a once-weekly oral monotherapy in patients aged 6 months to 25 years with relapsed or progressive pLGG with a known activating BRAF alteration. The presentation will showcase more than 36 months of follow-up data, demonstrating durable responses and clinical stability off treatment, as well as newly disclosed treatment-free interval data.</p>\n\n<p>Investors are reacting positively to this news, as the extended follow-up data and treatment-free interval information could potentially strengthen OJEMDA's position in the pediatric brain cancer treatment landscape. The presentation by Dr. Cassie Klein from the Children's Hospital of Pennsylvania on November 23, 2025, is highly anticipated and could provide further insights into the drug's efficacy and long-term benefits for young patients with this challenging form of brain cancer.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DAWN","symbol_name":"Day One Biopharmaceuticals Inc.","start_time":0,"source_url":"","article_id":"1119742553","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1119742553","pubTimestamp":1762789903,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Day One Biopharmaceuticals Inc. (DAWN) stock is soaring 5.04% in pre-market trading on Monday, following the announcement of new data from its OJEMDA™ (tovorafenib) trial in pediatric low-grade...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"DAWN":"Day One Biopharmaceuticals Inc."},"translate_title":"股票追踪|Day One Biopharmaceuticals因OJEMDA前景看好而飙升5.04%™儿童脑癌试验结果","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DAWN":1},"content_text":"Day One Biopharmaceuticals Inc. (DAWN) stock is soaring 5.04% in pre-market trading on Monday, following the announcement of new data from its OJEMDA™ (tovorafenib) trial in pediatric low-grade glioma (pLGG) to be presented at the upcoming Society for Neuro-Oncology (SNO) Annual Meeting.\nThe company revealed that updated results from the registrational Phase 2 FIREFLY-1 trial will be presented in an oral session at the SNO meeting, scheduled for November 19-23, 2025. The trial evaluates tovorafenib as a once-weekly oral monotherapy in patients aged 6 months to 25 years with relapsed or progressive pLGG with a known activating BRAF alteration. The presentation will showcase more than 36 months of follow-up data, demonstrating durable responses and clinical stability off treatment, as well as newly disclosed treatment-free interval data.\nInvestors are reacting positively to this news, as the extended follow-up data and treatment-free interval information could potentially strengthen OJEMDA's position in the pediatric brain cancer treatment landscape. The presentation by Dr. Cassie Klein from the Children's Hospital of Pennsylvania on November 23, 2025, is highly anticipated and could provide further insights into the drug's efficacy and long-term benefits for young patients with this challenging form of brain cancer.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}